Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.

Cross-Sectional Studies Gastrointestinal Microbiome HIV Infections / diagnosis HIV-1 Humans Microbiota Viremia
Antiretroviral therapy Cytokines HIV Immunological responders Inflammation Microbiome-immunity axis Microbiota Short chain fatty acid Viremia

Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
14 02 2022
Historique:
received: 28 05 2021
revised: 30 07 2021
accepted: 13 01 2022
entrez: 23 3 2022
pubmed: 24 3 2022
medline: 25 3 2022
Statut: ppublish

Résumé

Human immunodeficiency virus type 1 (HIV-1) infection is characterized by persistent systemic inflammation and immune activation, even in patients receiving effective antiretroviral therapy (ART). Converging data from many cross-sectional studies suggest that gut microbiota (GM) changes can occur throughout including human immunodeficiency virus (HIV) infection, treated by ART; however, the results are contrasting. For the first time, we compared the fecal microbial composition, serum and fecal microbial metabolites, and serum cytokine profile of treatment To compare for the first time the fecal microbial composition, serum and fecal microbial metabolites, and serum cytokine profile of treatment We enrolled 12 treatment We first compared microbiota signatures, FFA levels, and cytokine profile before starting ART and after reaching virological suppression. Modest alterations were observed in microbiota composition, in particular in the viral suppression condition, we detected an increase of Our results provided an additional perspective about the impact of HIV infection, ART, and immune recovery on the "microbiome-immunity axis" at the metabolism level. These factors can act as indicators of the active processes occurring in the gastrointestinal tract. Individuals with HIV-1 infection, before ART and after reaching virological suppression with 24 wk of ART, displayed a microbiota with unchanged overall bacterial diversity; moreover, their systemic inflammatory status seems not to be completely restored. In addition, we confirmed the role of the GM metabolites in immune reconstitution.

Sections du résumé

BACKGROUND
Human immunodeficiency virus type 1 (HIV-1) infection is characterized by persistent systemic inflammation and immune activation, even in patients receiving effective antiretroviral therapy (ART). Converging data from many cross-sectional studies suggest that gut microbiota (GM) changes can occur throughout including human immunodeficiency virus (HIV) infection, treated by ART; however, the results are contrasting. For the first time, we compared the fecal microbial composition, serum and fecal microbial metabolites, and serum cytokine profile of treatment
AIM
To compare for the first time the fecal microbial composition, serum and fecal microbial metabolites, and serum cytokine profile of treatment
METHODS
We enrolled 12 treatment
RESULTS
We first compared microbiota signatures, FFA levels, and cytokine profile before starting ART and after reaching virological suppression. Modest alterations were observed in microbiota composition, in particular in the viral suppression condition, we detected an increase of
CONCLUSION
Our results provided an additional perspective about the impact of HIV infection, ART, and immune recovery on the "microbiome-immunity axis" at the metabolism level. These factors can act as indicators of the active processes occurring in the gastrointestinal tract. Individuals with HIV-1 infection, before ART and after reaching virological suppression with 24 wk of ART, displayed a microbiota with unchanged overall bacterial diversity; moreover, their systemic inflammatory status seems not to be completely restored. In addition, we confirmed the role of the GM metabolites in immune reconstitution.

Identifiants

DOI: 10.3748/wjg.v28.i6.635 PMID: 35317423 PMC: PMC8900548
pubmed: 35317423
doi: 10.3748/wjg.v28.i6.635
pmc: PMC8900548
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

635-652

Informations de copyright

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors declare that they have no competing interests to disclose.

Références

Sci Rep. 2018 Sep 24;8(1):14277
pubmed: 30250162
Gastroenterology. 2010 Oct;139(4):1289-300
pubmed: 20600014
Mucosal Immunol. 2014 Jul;7(4):983-94
pubmed: 24399150
Emerg Microbes Infect. 2018 Jun 22;7(1):113
pubmed: 29934497
Microbes Infect. 2020 Oct;22(9):474-480
pubmed: 32534178
Curr Opin HIV AIDS. 2018 Jan;13(1):53-60
pubmed: 29028667
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Sci Rep. 2021 Jan 13;11(1):960
pubmed: 33441754
Genome Med. 2016 Jul 13;8(1):75
pubmed: 27412252
Cell Host Microbe. 2015 May 13;17(5):662-71
pubmed: 25865369
Adv Immunol. 2013;119:51-83
pubmed: 23886064
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490669
Genome Biol. 2014;15(7):R89
pubmed: 25146375
PLoS Pathog. 2017 Nov 2;13(11):e1006624
pubmed: 29095912
Microbiome. 2019 May 11;7(1):73
pubmed: 31078141
J Neuroimmunol. 2005 Nov;168(1-2):154-63
pubmed: 16091292
BMC Microbiol. 2021 Jan 6;21(1):11
pubmed: 33407128
Curr HIV Res. 2019;17(1):13-25
pubmed: 30854974
J Crohns Colitis. 2021 Sep 25;15(9):1500-1516
pubmed: 33611347
Immunol Rev. 2013 Jul;254(1):326-42
pubmed: 23772629
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Microbiome. 2013 Oct 12;1(1):26
pubmed: 24451087
Annu Rev Immunol. 2012;30:149-73
pubmed: 22224779
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Top Antivir Med. 2015 Mar-Apr;23(1):56-65
pubmed: 25965312
J Immunol. 2012 Jul 15;189(2):885-96
pubmed: 22689879
J Infect Dis. 2015 Jan 1;211(1):19-27
pubmed: 25057045
AIDS. 2018 Jun 19;32(10):1229-1237
pubmed: 29683848
Genome Biol. 2014;15(12):550
pubmed: 25516281
Clin Pharmacol Ther. 2016 Jun;99(6):600-11
pubmed: 26940481
EBioMedicine. 2016 Jan 28;5:135-46
pubmed: 27077120
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Immune Netw. 2014 Dec;14(6):277-88
pubmed: 25550694
Sci Transl Med. 2013 Jul 10;5(193):193ra91
pubmed: 23843452
Physiol Rev. 2001 Jul;81(3):1031-64
pubmed: 11427691
J Infect Dis. 2016 Oct 1;214 Suppl 2:S58-66
pubmed: 27625432
Cell Host Microbe. 2016 Mar 9;19(3):311-22
pubmed: 26962942
J Int AIDS Soc. 2017 Mar 8;20(1):21526
pubmed: 28362071
Nature. 2013 Dec 19;504(7480):451-5
pubmed: 24226773
PLoS Pathog. 2014 Feb 20;10(2):e1003829
pubmed: 24586144
Cell Host Microbe. 2013 Sep 11;14(3):329-39
pubmed: 24034618
Curr Opin HIV AIDS. 2018 Jan;13(1):22-27
pubmed: 29035948
World J Gastroenterol. 2019 Sep 28;25(36):5543-5558
pubmed: 31576099
J Proteome Res. 2005 Mar-Apr;4(2):227-31
pubmed: 15822897
Viral Immunol. 2012 Aug;25(4):333-7
pubmed: 22788418
Biochim Biophys Acta. 2010 Mar;1801(3):392-9
pubmed: 19800025
Biometrics. 2015 Dec;71(4):1042-9
pubmed: 26038228
Mucosal Immunol. 2015 Sep;8(5):1009-20
pubmed: 25586559
Science. 2011 Oct 7;334(6052):105-8
pubmed: 21885731
Open Forum Infect Dis. 2016 Feb 09;3(1):ofw032
pubmed: 26989755
Front Cell Infect Microbiol. 2021 May 18;11:646467
pubmed: 34084754
Mucosal Immunol. 2015 Jul;8(4):760-72
pubmed: 25407519
Trends Microbiol. 2013 Jan;21(1):6-13
pubmed: 23062765
Clin Transl Immunology. 2016 Apr 22;5(4):e73
pubmed: 27195116
AIDS Res Hum Retroviruses. 2013 Apr;29(4):691-7
pubmed: 23151174
Curr Opin HIV AIDS. 2010 Nov;5(6):498-503
pubmed: 20978393
Clin Microbiol Rev. 2013 Jan;26(1):2-18
pubmed: 23297256
Sci Rep. 2017 Mar 06;7:43741
pubmed: 28262770
J Virol. 2003 Nov;77(21):11708-17
pubmed: 14557656
Clin Exp Immunol. 2000 Mar;119(3):479-85
pubmed: 10691920
J Leukoc Biol. 2014 Dec;96(6):1055-63
pubmed: 25157027
Gut. 1987 Oct;28(10):1221-7
pubmed: 3678950
PLoS Pathog. 2020 Mar 2;16(3):e1008333
pubmed: 32119719
Eur J Nutr. 2020 Aug;59(5):2011-2024
pubmed: 31292752
Crit Rev Immunol. 2003;23(1-2):45-64
pubmed: 12906259
AIDS Res Ther. 2016 Apr 11;13:19
pubmed: 27073405
Curr HIV/AIDS Rep. 2012 Jun;9(2):139-47
pubmed: 22528766
JAMA Netw Open. 2020 Jun 1;3(6):e207954
pubmed: 32539152
J Infect Dis. 2020 Jan 14;221(3):483-492
pubmed: 31549151
FEMS Microbiol Lett. 2009 May;294(1):1-8
pubmed: 19222573
PLoS One. 2014 Jan 30;9(1):e85798
pubmed: 24497929
BMC Infect Dis. 2014 Mar 04;14:122
pubmed: 24589015
BMC Med. 2016 Jun 03;14(1):83
pubmed: 27256449
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
Nutrients. 2021 Feb 26;13(3):
pubmed: 33652681
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Front Immunol. 2021 Feb 26;12:639291
pubmed: 33717191
AIDS. 2017 Feb 20;31(4):511-521
pubmed: 28002063
Front Microbiol. 2018 Jul 02;9:1451
pubmed: 30034377
AIDS. 2015 Nov 28;29(18):2409-18
pubmed: 26355675
J Exp Med. 2004 Sep 20;200(6):761-70
pubmed: 15365095
Curr Opin HIV AIDS. 2018 Jan;13(1):73-80
pubmed: 29045252

Auteurs

Edda Russo (E)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Giulia Nannini (G)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Gaetana Sterrantino (G)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Seble Tekle Kiros (ST)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Vincenzo Di Pilato (V)

Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa 16126, Italy.

Marco Coppi (M)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Simone Baldi (S)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Elena Niccolai (E)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Federica Ricci (F)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Matteo Ramazzotti (M)

Department of Biomedical, Experimental and Clinical "Mario Serio", University of Florence, Florence 50134, Italy.

Marco Pallecchi (M)

Department of Biomedical, Experimental and Clinical "Mario Serio", University of Florence, Florence 50134, Italy.

Filippo Lagi (F)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Gian Maria Rossolini (GM)

Microbiology and Virology Unit, Florence Careggi University Hospital, University of Florence, Florence 50134, Italy.

Alessandro Bartoloni (A)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy.

Gianluca Bartolucci (G)

Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence 50019, Italy.

Amedeo Amedei (A)

Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy. aamedei@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Effects of viremia and CD4 recovery on gut...
questionsmedicales.fr › Environnement et santé publique › Environnement › Écosystème › Biodiversité › Biote › Microbiote › Microbiome gastro-intestinal › Effects of viremia and CD4 recovery on gut...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Effects of viremia and CD4 recovery on gut...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Effects of viremia and CD4 recovery on gut...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Effects of viremia and CD4 recovery on gut...
questionsmedicales.fr › Environnement et santé publique › Environnement › Écosystème › Biodiversité › Biote › Microbiote › Effects of viremia and CD4 recovery on gut...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Virémie › Effects of viremia and CD4 recovery on gut...